Pavel Kubarkov /
29 June 2016Americas

BTG and Janssen sue Glenmark over Zytiga generic bid

BTG International and Janssen have sued Glenmark Pharmaceuticals claiming it has infringed a patent covering the Zytiga (abiraterone acetate) drug.

Zytiga is a prostate cancer drug which works by reducing androgen production in the body. Androgen is a male hormone that can promote tumour growth in the prostate gland.

According to the complaint, Glenmark filed an Abbreviated New Drug Application with the US Food and Drug Administration on May 18 in which it sought approval to market a generic version of the drug.

The case, filed at the US District Court for the District of New Jersey on June 24, centres on US patent number, 8,822,438.

BTG International has a licence from Janssen for Zytiga in both the US and EU.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at